| Literature DB >> 22312574 |
Nana Kofi Ayisi1, Regina Appiah-Opong, Ben Gyan, Kwasi Bugyei, Fred Ekuban.
Abstract
A tetrazolium-based colorimetric selective assay (MTT-based CSA) was developed to assess the selectivity of antimalarial drugs. This in vitro assay, unlike all others, measures the ability of drugs to indirectly protect red blood cells (RBCs) from Plasmodium-falciparum-induced destruction. Optimum incubation time and number of cells needed were 5 days and 23 × 10(6) RBCs per well, respectively. A parasitemia range of 0.375% to 3% was found to be suitable for this assay. The MTT-based CSA determined anti-P. falciparum strain DD2 activity of chloroquine at a higher 50% effective concentration (EC(50)) value (21.0 μg/mL) than the isotopic microtest (10.0 μg/mL). Artesunate and oxytetracycline achieved 90% effect against DD2 with minimal or no toxicity to RBCs. Against chloroquine sensitive strain 3D7, chloroquine and Alchornea cordifolia had EC(50) values of 0.025 μg/mL and 4.9 μg/mL respectively, and selective index (SI) values of >2,000 and >69.4 μg/mL, respectively.Entities:
Year: 2011 PMID: 22312574 PMCID: PMC3265290 DOI: 10.4061/2011/816250
Source DB: PubMed Journal: Malar Res Treat
Figure 1Effects of number of red blood cells (a) and parasitemia (b) on P. falciparum cytopathicity, that is, optical density of mock-infected RBCs minus optical density of parasite-infected RBCs [(ODC)mock − (ODC)infected]. Infection was done with strain 3D7.
Figure 2Anti-P. falciparum activity and toxicity of chloroquine (purchased from Sigma) tested in the IMT (a) and MTT-based CSA (b) using parasite strain DD2.
Effects of drugs and plant extracts against P. falciparum strains DD2 (A) and 3D7 (B) infection in RBCs.
| Drug | EC50 | EC90 | CC50 | SI (CC50/EC50) | |
|---|---|---|---|---|---|
| (A) | Sigma CQa∗ | 10.0 | 20.4 | NA | NA |
| Sigma CQb∗ | 21.0 | 77.9 | 82.7 | 3.9 | |
| Formulated CQb | 32.6 | >50c | >50c | >1.5 | |
| GHX-6Lb | >445c | >445c | >445c | ND | |
| GHX-26Fb | 272.8 | >340c | >340c | >1.2 | |
| (B) | Formulated CQb | 0.025 | 0.05 | >50c | >2,000 |
| GHX-6Lb | >445c | >445c | >445c | ND | |
| GHX-26Fb | 4.9 | 16.2 | >340c | >69.4 |
aTested by IMT, bTested by MTT-based CSA, *Parasitemia used was 1.5%. For the other tests, parasitemia used was 3.0%, cHighest concentration tested, SI: selective index, NA: not applicable, ND: not determined.
Figure 3Anti-P. falciparum activity and toxicity of formulated chloroquine (a) and plant extract GHX-26F (b) tested in the MTT-based CSA using parasite strains 3D7 and DD2.
Figure 4Anti-P. falciparum activity and toxicity of formulated proguanil (a), artesunate (b), and oxytetracycline (c) tested in the MTT-based CSA using parasite strain DD2.
Figure 5Photographs of parasite strain 3D7-infected (bottom three replicates) and -uninfected (top three replicates) RBCs treated with formulated chloroquine (a), plant extract GHX-6L (b), and plant extract GHX-26F (c) after the tetrazolium reaction. Concentrations are given as μg/mL.